Dimitrios H. Roukos

Dimitrios H. Roukos's AcademicInfluence.com Rankings

Dimitrios H. Roukos

Biology

#13218

World Rank

#16751

Historical Rank

Computational Biology

#305

World Rank

#306

Historical Rank

Genetics

#1470

World Rank

#1572

Historical Rank

Molecular Biology

#2209

World Rank

#2243

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Dimitrios H. Roukos Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dimitrios H. Roukos's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC–EURGAST) (2006) (334)
Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). (2006) (331)
The role of heat shock proteins in cancer. (2015) (259)
The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. (2004) (182)
Perspectives in the treatment of gastric cancer (2005) (159)
Fruit and vegetable intake and the risk of gastric adenocarcinoma: A reanalysis of the european prospective investigation into cancer and nutrition (EPIC‐EURGAST) study after a longer follow‐up (2012) (121)
Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer (2007) (120)
The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations (2007) (120)
Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance (2009) (118)
Current Advances and Changes in Treatment Strategy May Improve Survival and Quality of Life in Patients With Potentially Curable Gastric Cancer (1999) (113)
Genome-wide association studies: how predictable is a person’s cancer risk? (2009) (113)
Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome (2007) (108)
Individual genomes and personalized medicine: life diversity and complexity. (2010) (108)
Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: A prospective with quality control 10-year follow-up study (2001) (100)
Novel clinico–genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care (2010) (99)
Application of microRNAs in diabetes mellitus. (2014) (99)
Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice (2009) (97)
A new paradigm emerges from the study of de novo mutations in the context of neurodevelopmental disease (2013) (92)
From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine (2013) (90)
More Controversy than Ever – Challenges and Promises Towards Personalized Treatment of Gastric Cancer (2008) (89)
Personal Genomics and Genome-Wide Association Studies: Novel Discoveries but Limitations for Practical Personalized Medicine (2009) (87)
Distal Gastric Cancer and Extensive Surgery: A New Evaluation Method Based on the Study of the Status of Residual Lymph Nodes After Limited Surgery (2000) (86)
Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. (2010) (85)
CDH1 Testing: Can it Predict the Prophylactic or Therapeutic Nature of Total Gastrectomy in Hereditary Diffuse Gastric Cancer? (2009) (84)
Extended (D2) Lymph Node Dissection for Gastric Cancer: Do Patients Benefit? (2000) (83)
Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks (2011) (83)
Targeting the optimal extent of lymph node dissection for gastric cancer (2002) (82)
Breast-cancer stromal cells with TP53 mutations. (2008) (81)
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer (2009) (80)
Genotype–phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment (2010) (79)
Perspectives and Risks of Breast-Conservation Therapy for Breast Cancer (2003) (79)
Systems medicine: a real approach for future personalized oncology? (2010) (78)
Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention (2009) (78)
Genome-Wide Association Studies and Aggressive Surgery Toward Individualized Prevention, and Improved Local Control and Overall Survival for Gastric Cancer (2009) (78)
Is it Time to Change Surgical Strategy for Gastric Cancer in the United States? (2004) (76)
Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. (2008) (76)
Radiation therapy for breast cancer. (2009) (76)
Factors increasing local recurrence in breast-conserving surgery (2005) (75)
Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer (2006) (75)
Early-Stage Gastric Cancer: A Highly Treatable Disease (2004) (75)
Complete genome sequencing and network modeling to overcome trastuzumab resistance. (2010) (74)
Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance (2004) (74)
Role of surgery in the prophylaxis of hereditary cancer syndromes (2002) (74)
Personalized cancer diagnostics and therapeutics (2009) (74)
Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. (2009) (74)
Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery (2008) (73)
Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. (2009) (72)
Human Genetic and Structural Genomic Variation: Would Genome-Wide Association Studies Be the Solution for Cancer Complexity Like Alexander the Great for the “Gordian Knot”? (2009) (72)
Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies (2008) (71)
Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine (2009) (71)
Level I Evidence in Support of Perioperative Chemotherapy for Operable Gastric Cancer: Sufficient for Wide Clinical Use? (2007) (71)
Quality of surgery determinant for the outcome of patient with gastric cancer (2002) (69)
Adjuvant chemoradiotherapy in gastric cancer: Wave goodbye to extensive surgery? (2002) (69)
Genomics and challenges toward personalized breast cancer local control. (2008) (69)
Linking contralateral breast cancer with genetics. (2008) (69)
Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? (2010) (69)
Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. (2007) (67)
From tumor size and HER2 status to systems oncology for very early breast cancer treatment (2010) (67)
Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers ofBRCA1 orBRCA2 mutations (2002) (67)
Robotic surgery for rectal cancer: may it improve also survival? (2008) (66)
Laparoscopic gastrectomy: advances enable wide clinical application (2008) (64)
Next-generation sequencing and epigenome technologies: potential medical applications (2010) (62)
Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. (2009) (59)
Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. (2011) (50)
Isolated tumor cells in breast cancer. (2009) (49)
Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends (2010) (48)
Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? (2009) (47)
Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST) (2007) (46)
Relevant prognostic factors in gastric cancer. (2000) (45)
Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X (2012) (45)
Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. (2019) (38)
Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. (2010) (37)
A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach (1990) (37)
Continuous intraoperative neuromonitoring in thyroid surgery: Safety analysis of 400 consecutive electrode probe placements with standardized procedures (2016) (36)
HER2 and response to paclitaxel in node-positive breast cancer. (2008) (34)
Impact of spleen preservation in patients with gastric cancer. (2005) (33)
Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. (2017) (33)
Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? (2008) (32)
Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets (2011) (30)
Potential of antibody–drug conjugates and novel therapeutics in breast cancer management (2014) (29)
Laparoscopic gastrectomy for gastric cancer: current evidences. (2014) (27)
Prognostic relevance of systemic lymph node dissection in gastric carcinoma. (1995) (24)
Clinical Cancer Genome and Precision Medicine (2012) (24)
‘Big’ science: genome regulatory networks and novel molecular tools to improve health (2011) (21)
Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy. (2019) (21)
Translating epigenetics into an anticancer drug pipeline for solid tumors (2011) (20)
Clinical relevance of cancer genome sequencing. (2013) (20)
Gastric Cancer: Introduction, Pathology, Epidemiology (2002) (20)
Dynamic genome and transcriptional network‐based biomarkers and drugs: precision in breast cancer therapy (2018) (20)
Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond (2010) (19)
Limitations in Controlling Risk for Recurrence After Curative Surgery for Advanced Gastric Cancer Are Now Well-Explained by Molecular-Based Mechanisms (2001) (19)
Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks (2010) (19)
Chromatin: a key player in complex gene regulation and future cancer therapeutics. (2011) (18)
Circulating tumor DNA: new horizons for improving cancer treatment. (2015) (18)
Robotic versus laparoscopic surgery: perspectives for tailoring an optimal surgical option (2011) (17)
Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies. (2016) (17)
Spatiotemporal individual genome code–lifestyle network: revolutionizing personal diagnostics (2012) (17)
Novel next-generation sequencing and networks-based therapeutic targets: realistic and more effective drug design and discovery. (2014) (17)
PLX4032 and melanoma: resistance, expectations and uncertainty (2011) (16)
BMI and lymph node ratio may predict clinical outcomes of gastric cancer. (2014) (16)
From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers (2017) (15)
EGFR as a Prognostic Marker for Gastric Cancer (2008) (15)
Epigenetics in Gastric Cancer: Challenges for Clinical Implications (2009) (15)
Emerging personalized oncology: sequencing and systems strategies. (2012) (14)
Research and clinical applications of cancer genome sequencing (2013) (14)
Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer (2019) (14)
Disrupting cancer cells’ biocircuits with interactome-based drugs: is ‘clinical’ innovation realistic? (2012) (14)
Longevity with systems medicine? Epigenome, genome and environment interactions network. (2012) (14)
Gene-Expression Profile: The Future in the Outcome Prediction and Treatment of Breast Cancer (2003) (13)
Differential signaling transduction networks for clinical robustness (2012) (12)
Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets (2013) (12)
Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. (2018) (12)
Biotechnological, genomics and systems–synthetic biology revolution: redesigning genetic code for a pragmatic systems medicine (2012) (12)
Integrated clinical genomics: new horizon for diagnostic and biomarker discoveries in cancer (2013) (11)
Laparoscopic and robotic rectal cancer resection: expectations for improving oncological outcomes. (2010) (11)
Intraoperative Neuromonitoring of the External Branch of the Superior Laryngeal Nerve during Thyroidectomy: The Need for Evidence-Based Data and Perioperative Technical/Technological Standardization (2014) (10)
[Prognostic significance of the Lauren classification of patients with stomach carcinoma. A statistical analysis of long-term results following gastrectomy]. (1989) (9)
Contralateral prophylactic mastectomy: mind the genetics. (2008) (9)
Genome network medicine: innovation to overcome huge challenges in cancer therapy (2014) (9)
Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance (2012) (9)
Translating cancer genomes sequencing revolution into surgical oncology practice. (2012) (9)
Innovation versus evidence: to trust direct-to-consumer personal genomic tests? (2011) (8)
Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. (2011) (8)
Circulating free DNA in plasma or serum as biomarkers of carcinogenesis in colon cancer. (2015) (8)
Nipple-Sparing Mastectomy: Overcoming Oncological Outcomes Challenges (2009) (8)
Evaluating Cancer Risks in BRCA Mutation Carriers (2005) (8)
Ovarian cancer screening and peritoneal carcinomatosis: standards, ‘omics’ and miRNAs for personalized management (2011) (7)
Gastric cancer in Europe. (2008) (7)
Dynamic sequencing of circulating tumor DNA: novel noninvasive cancer biomarker. (2014) (7)
Progress, challenges and new genome-based concepts in the multidisciplinary treatment of gastric cancer (2011) (7)
Fruits and vegetables: do they protect from gastric cancer? (2003) (7)
Gastric cancer guidelines and genome differences between Japan and the west. (2013) (7)
Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: can this be translated to patient benefit? (2014) (7)
Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology (2018) (6)
Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer—Promises and Reality (2008) (6)
Genome network medicine: new diagnostics and predictive tools (2013) (6)
Treatment of Gastric Cancer: Early-Stage, Advanced-Stage Cancer, Adjuvant Treatment (2002) (6)
Innovative biomarker development for personalized medicine in breast cancer care. (2011) (6)
Identification of novel genes by whole-exome sequencing can improve gastric cancer precision oncology. (2017) (6)
Tumor heterogeneity-based resistance guides personalized cancer medicine. (2014) (6)
Cancer Genome Explosion and Systems Biology: Impact on Surgical Oncology? (2011) (6)
Novel clinico-genome network modeling for revolutionizing (2010) (6)
Can VEGF-D and VEGFR-3 be used as biomarkers for therapeutic decisions in patients with gastric cancer? (2006) (5)
Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges (2013) (5)
Totally Laparoscopic Gastrectomy: A Reality for USA and Europe? (2009) (5)
Novel cancer drugs based on epigenetics, miRNAs and their interactions. (2011) (5)
Exploring the role of BRCA1, BRCA2 and RAD51 as biomarkers for breast cancer. (2009) (5)
From standard to new genome-based therapy of gastric cancer (2015) (5)
[Surgical treatment and prognosis of stomach carcinoma with special reference to gastrectomy as a standard operation]. (1988) (5)
Endoscopic submucosal dissection: can it safely expand indications for a minimally invasive approach to patients with early gastric cancer? (2010) (5)
Surgery in the Era of Gene Expression Profiling–Based Prediction and Individualized, Neoadjuvant Breast Cancer Therapy: The Beginning of the End? (2006) (5)
Tumor Stage-Based Tailored Therapeutic Strategy: Rational Approach or New Trend? (2003) (5)
Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options (2011) (5)
Head and neck squamous cell carcinoma and human papillomavirus: epidemiology, treatment and future trends. (2015) (5)
Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy. (2017) (5)
Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer Diagnosis—Invited Critique (2003) (4)
Targeted therapy: overcoming drug resistance with clinical cancer genome (2012) (4)
Deep sequencing and integrative genome analysis: approaching a new class of biomarkers and therapeutic targets for breast cancer. (2013) (4)
Totally intracorporeal laparoscopic gastrectomy for gastric cancer (2010) (4)
Gastric Cancer : Diagnosis , Staging , Prognosis (2005) (4)
Letter to the Editor: Breast Cancer in Young Women in Africa: Are There Genetic and Clinical Differences with European Ancestry Patients? (2010) (4)
The Era of Robotic Surgery for Colorectal Cancer (2009) (4)
Advantages of staging laparoscopy in gastric cancer: they are so obvious that they are not evident. (2015) (4)
Palbociclib: an approval at last for HER2-negative breast cancer. (2016) (4)
Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends (2013) (4)
The evolution of high-throughput sequencing technologies: from Sanger to single-molecule sequencing (2013) (4)
Genome diagnostics: next-generation sequencing, new genome-wide association studies and clinical challenges (2011) (4)
Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification? (2006) (4)
Proof-of-Concept Changes Treatment Guidelines for Gastric Cancer (2004) (3)
Targeting dynamics of subclones of GI, liver and pancreatic cancers (2016) (3)
HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer (2008) (3)
Prediction of pancreatic cancer risk and therapeutic response with next-generation sequencing. (2018) (3)
Carcinogenesis of Breast Cancer : Advances and Applications (2005) (3)
Missing heritability, next-generation genome-wide association studies and primary cancer prevention: an Atlantean illusion? (2011) (3)
Next-generation sequencing-based testing for cancer mutational landscape diversity: clinical implications? (2012) (3)
Breast-Conserving Surgery and Risk of Positive Margins in Breast Cancer (2003) (3)
Primary liver cancer genome sequencing: translational implications and challenges (2017) (3)
From traditional molecular biology to network oncology. (2011) (3)
HER-2-Negative Breast Cancer Limitations and Next-Generation Sequencing Technology Promises (2010) (3)
Early solid tumor diagnosis through next-generation sequencing of cell-free DNA. (2018) (3)
Omitting Axilla Lymphadenectomy Even by Positive Sentinel Lymph Node: A Change in Breast Cancer Treatment Practice (2011) (3)
Breast and Gastric Cancer: Comparing What We Learn (2003) (3)
Follow-Up for Gastric Cancer: How Extensive and Intensive Should It Be? (2010) (3)
Novel translational therapeutic strategy by sequencing primary liver cancer genomes. (2017) (3)
Mapping inherited and somatic variation in regulatory DNA: new roadmap for common disease clinical discoveries (2013) (3)
Beyond BRCA1/2: polygenic, 'polyfunctional' molecular circuitry model to predict breast cancer risk. (2013) (2)
Cancer genome sequencing and functional genomics: from translational to clinical medicine. (2011) (2)
Comparative-effectiveness research to standardize retrieved nodes for quality control in colorectal cancer. (2010) (2)
Personalizing prophylactic surgery in cancer: current practice and future perspectives from new genome-wide association studies (2011) (2)
Does neoadjuvant versus adjuvant systemic treatment improve outcomes in breast cancer? (2005) (2)
Targeted agents for advanced thyroid cancer: "knowledge is power" - the role of multikinase inhibitors. (2014) (2)
Cancer heterogeneity and signaling network-based drug target. (2013) (2)
Next-Generation Sequencing & Molecular Diagnostics (2013) (2)
From personalized to precision cancer medicine. (2020) (2)
New molecular oncology-changing era: prospects and challenges of cancer genome and integrative systems biology (2011) (2)
Proof-of-Concept Pilot Study on Comprehensive Spatiotemporal Intra-Patient Heterogeneity for Colorectal Cancer With Liver Metastasis (2021) (2)
Challenges in Personalizing Decisions on Whole, Partial or No Breast Irradiation and Extent of Surgery for Early Breast Cancer (2009) (2)
Standards, advances and challenges in laparoscopic total mesorectal excision (2010) (2)
Breast cancer genome analysis in time and space: biomarker development strategy. (2018) (2)
Predictive and patient-monitoring biomarkers: precision in the management of colorectal cancer. (2020) (2)
Limitations of Isolated Tumor Cells in Gastric Cancer: Heterogeneity Requests Systems Biology Approaches Towards Personalized Medicine (2009) (2)
Targeting the individual cancer patient (2011) (2)
Genomic and transcriptional heterogeneity-based precision in personalized treatment for breast cancer. (2019) (2)
Pharmacogenomics for tailoring cardiovascular and anticancer drugs: from genotyping to whole-genome sequencing. (2011) (2)
Cancer genome sequencing and potential application in oncology. (2010) (2)
New target therapies for patients with neuroendocrine tumors of the pancreas (2011) (2)
Intratumor heterogeneity: predicting and preventing therapeutic resistance. (2016) (2)
Breast-Conserving Treatment for Breast Cancer: Rational, Current Reality & Limitations (2003) (2)
Preservation vs Resection of the Spleen for Gastric Cancer (2005) (2)
New horizons for targeted treatment of neuroendocrine tumors. (2016) (2)
Does Lymphadenectomy Improve Survival of Patients with Solid Tumors? (2007) (2)
Risks and Benefits of Risk-Reducing Surgery in Inherited Breast and Gastric Cancer Susceptibility (2005) (2)
Breakthrough targeted therapeutic approaches to squamous cell carcinoma of the head and neck. (2015) (2)
Dynamics of genome ‘iPOP’: predicting disease or ‘narciss-ome’? (2012) (1)
From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment. (2013) (1)
Precise predictive and therapeutic strategy for breast cancer. (2018) (1)
It Is Still Not the Time to Change Surgical Strategy for Gastric Cancer (2005) (1)
Tumor heterogeneity-driven individualized therapy. (2020) (1)
From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer. (2014) (1)
Molecular landscape of pancreatic cancer: challenges and clinical implications. (2017) (1)
Decoding coronary artery disease: somatic mosaicism and genomics for personal and population risk prediction. (2013) (1)
Genomic heterogeneity: next-generation sequencing enables biomarker identification for hepatocellular carcinoma. (2017) (1)
Challenges in Developing Robust Genetic Markers and Targets to Predict and Prevent Distant and Peritoneal Recurrence in Gastric Cancer (2009) (1)
Contralateral Prophylactic Mastectomy Overtreatment: Expectations from Personal Genomics for Tailored Breast Cancer Surgery (2010) (1)
Ten Years after Human Genome Sequencing: Is Personalized Breast Screening and Prevention Reality? (2010) (1)
Clinical Proteomics in Cancer Research (2013) (1)
[Therapy of stomach carcinoma in older people]. (1988) (1)
Increased risk of local recurrence after breast-conserving therapy in young patients. (2008) (1)
Preventing Familial Breast and Ovarian Cancer: Major Research Advances with Little Implication (2011) (1)
Quality Control in Colorectal Cancer Care: How Many Lymph Nodes Should Be Harvested? (2010) (1)
Integrating NGS and third-generation sequencing technologies into clinical genomic medicine (2013) (1)
Precision in cancer pharmacogenomics. (2020) (1)
Is an aromatase inhibitor more effective than tamoxifen in neoadjuvant endocrine therapy for breast cancer? (2006) (1)
Next-Generation Sequencing in Cancer Epigenomics and Potential Clinical Applications (2013) (1)
Designing next-generation drug development in precision medicine (2016) (0)
Precision oncology in patients with nonmetastatic disease: emerging reality or illusion. (2019) (0)
Targeted Therapy and Novel Agents for the Treatment of Gastric Cancer: A View Toward the Future (2015) (0)
Gene expression 'signature' limitations and genome architecture-based perspectives for robust cancer biomarkers. (2013) (0)
Translating complex genomic discoveries into molecular diagnostic tests (2013) (0)
De novo mutations, protein–protein interactions and functional regulatory networks toward novel diagnostics in autism (2012) (0)
TITLE PAGE TITLE: Proof-of-concept pilot study on comprehensive spatiotemporal intra-patient heterogeneity for colorectal cancer with liver metastasis (2021) (0)
the cancer genome structure and function, shaping the future of personalized oncology." (2012) (0)
Genome-based diagnostics and predictive tools: a new epoch for breast cancer management. (2012) (0)
PERSPECTIVE Prevention of Epithelial Cancer: The Challenge for the 21st Century (2004) (0)
Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era. (2012) (0)
The wide heterogeneity and high complexity of the human genome in health and disease explains why genomic medicine has not been achieved yet. (2011) (0)
Breakthrough therapies in melanoma. (2014) (0)
Esophagus and Gastric Cancer: How Surgeon’s Experience and Personal Genomics May Improve Locoregional Control and Survival (2008) (0)
Thresholds and combined quality control in the multimodal treatment of colorectal cancer (2010) (0)
Regorafenib: a newly approved drug for advanced hepatocellular carcinoma. (2017) (0)
Precision in personalized prediction-based medicine. (2018) (0)
Magnetic Resonance Imaging and Potential Impact on Extent of Surgery in Breast Cancer (2009) (0)
Gastric Cancer Causation (2002) (0)
Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development. (2018) (0)
he evident high lifetime risk of breast cancer (45%-85%) and ovarian cancer (15%-40%) in BRCA1 or BRCA2 muta- tion carriers has established a form of genetic testing essential for decision making between risk-reducing bilateral mastectomy or oophorectomy (2016) (0)
"Chromatin controls gene expression and several other cellular functions such as transcription, DNA repair, DNA replication and development by both its components, namely DNA sequence as well as histone and nonhistone proteins." (2011) (0)
Adjuvant chemotherapy in gastric cancer. (2000) (0)
Advances in Laparoscopic Gastrectomy Expand Clinical Use (2008) (0)
Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. (2009) (0)
new studies may reveal underlying rare genetic variations distinct for gastric cancer in east Asia and the western world (2013) (0)
PERSPECTIVE Carcinogenesis of Breast Cancer: Advances and Applications (2004) (0)
Longitudinal ctDNA profiling in precision oncology and immunο-oncology. (2023) (0)
Standardizing Lymphadenectomy for Rectal Cancer. Author's reply (2010) (0)
Advances in Personalized Cancer Management (2011) (0)
Hope from Japan for esophagogastric cancers: esophagectomy and endoscopic submucosal dissection for gastric tube cancer (2010) (0)
New technology-based innovation changes surgical practice and research direction in solid cancers (2010) (0)
Circulating Cancer Cells: Could They Be Used in the Clinic as Recurrence Markers for Gastric and Colorectal Cancer? (2009) (0)
Improving Women's Health: Advances, Failures and Cancer Genome Prospects (2010) (0)
The ‘sequence everything’ approach and personalized clinical decision challenges (2012) (0)
International Randomized Trials’ Attention to Locoregional Breast Cancer Control and Promise of Personal Genomics and Whole-Genome Scans for Personalized Approaches (2008) (0)
Outcomes of breast cancer patients with and without BRCA1/2 mutations (2007) (0)
Caution in Adding Bevacizumab in the Adjuvant Treatment of Breast Cancer (2010) (0)
Standardizing lymphadenectomy for rectal cancer. (2010) (0)
Personalized genomic medicine: is a cancer care revolution achievable? (2011) (0)
Advances in locating lymph nodes by endoscopic ultrasound-guided fine-needle marking. (2010) (0)
From traditional to whole-genome sequencing biomarkers for gastric cancer. (2015) (0)
"To increase efficacy and overcome resistance to epigenetic therapy, the idea of the combination of DNMT and HDAC inhibitors has been developed. " (2011) (0)
Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer: What to Avoid. Preliminary Analysis of a Consecutive Series of Patients (2015) (0)
Network-based drugs: promise and clinical challenges in cardiovascular disease (2013) (0)
Impact of Final Margin Status on Ipsilateral Breast Tumor Recurrence Rates after Conservative Surgery and Radiation Therapy Author ( Institution ) Number of Patients ( Median f / u ) Endpoint Negative Close Positive (2005) (0)
Prevention of Epithelial Cancer : The Challenge for the 21 st Century (2005) (0)
Bench-top sequencing and clinical implementation: diagnostics and biomarkers challenges. (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dimitrios H. Roukos?

Dimitrios H. Roukos is affiliated with the following schools:

Dimitrios H. Roukos's Academic­Influence.com Rankings

Why Is Dimitrios H. Roukos Influential?

Dimitrios H. Roukos's Published Works

Published Works

What Schools Are Affiliated With Dimitrios H. Roukos?

Dimitrios H. Roukos's AcademicInfluence.com Rankings